Virtual Reality Visualization for Photogrammetric 3D Reconstructions of Cultural Heritage

H. Herrmann,Emiliano Pastorelli

DOI: https://doi.org/10.1007/978-3-319-13969-2_21

2014-09-17

Abstract:

What problem does this paper attempt to address?

Comparative evaluation of four rapid diagnostic tests that detect human Trypanosoma cruzi- specific antibodies to support diagnosis of Chagas Disease in urban population of Argentina

Rocío Rivero,M Soledad Santini,Constanza López-Albizu,Marcelo Rodriguez,Adriana Calbosa,Daniela Oliveto,Mónica Esteva,Margarita Bisio,Laura C Bohorquez,M. Soledad Santini,Laura C. Bohorquez

DOI: https://doi.org/10.1371/journal.pntd.0011997

2024-03-16

PLoS Neglected Tropical Diseases

Abstract:Chagas disease (CD), caused by the parasite Trypanosoma cruzi , is the most important endemic anthropozoonosis in Argentina. Since 2010, the World Health Organization has highlighted the urgent need to validate diagnostic systems that allow rapid detection of T . cruzi , infection in primary healthcare centers. Serological rapid diagnostic tests (RDTs) for T . cruzi , infection could be used to improve case management, as RDTs do not require specialized laboratories or highly trained staff to use them. We aimed to generate unbiased performance data of RDTs in Argentina, to evaluate their usefulness for improving T . cruzi , diagnosis rates. This is a retrospective, laboratory-based, diagnostic evaluation study to estimate the clinical sensitivity/specificity of four commercially available RDTs for T . cruzi , using the Chagas disease diagnostic algorithm currently used in Argentina as the reference standard. In total, 400 serum samples were tested, 200 from individuals with chronic T . cruzi infection and 200 from individuals not infected with T . cruzi . All results were registered as the agreement of at least two operators who were blinded to the reference standard results. The sensitivity estimates ranged from 92.5–100% (95% confidence interval (CI) lower bound 87.9–98.2%); for specificity, the range was 76–96% (95% CI lower bound 69.5–92.3%). Most RDTs evaluated showed performances comparable with the reference standard method, showing almost perfect concordance ( Kappa 0.76–0.92). Our study demonstrates that, under controlled laboratory conditions, commercially available RDTs for CD have a performance comparable to the Argentinian diagnostic algorithm, which is based on laboratory-based serological tests. For the next stage of our work, the RDTs will be evaluated in real-world settings. Trypanosoma cruzi is the causative agent of Chagas disease, the most significant transmissible disease between animals and humans in Argentina. It is estimated that two-thirds of individuals with the disease currently reside in urban areas, and globally, only 10% of those affected are aware of their condition. The diagnosis of chronic infection requires conducting at least two different laboratory tests mainly available at reference laboratories, which poses logistical and economic challenges for both the patients and the health systems, and it often results in limited access to high-quality diagnosis. Primary healthcare has the potential to address around 90% of the population's healthcare needs over their lifetime. Although there are rapid diagnostic tests for T . cruzi infection, that could be potentially incorporated at lower levels of the healthcare system in Argentina, there is a lack of independent evaluation of the available tests. In fact, since 2010 the World Health Organization emphasized the need of evaluating diagnostic tests that enable the rapid detection of T . cruzi infection in primary care centers. In this study, we assessed under controlled laboratory conditions the ability of the rapid diagnostic tests for confirming or ruling out the chronic infection in patients in Argentina.

tropical medicine,parasitology
Comparative evaluation of lateral flow assays to diagnose chronic Trypanosoma cruzi infection in Bolivia

Ronald López,Andrea García,José Jorge Chura Aruni,Victor Balboa,Andrea Rodríguez,Berra Erkosar,Aurélie Kamoun,Marcelo Rodriguez,Evelin Fortun,Laura C Bohorquez,Laura C. Bohorquez

DOI: https://doi.org/10.1371/journal.pntd.0012016

2024-03-05

PLoS Neglected Tropical Diseases

Abstract:Bolivia has the highest incidence of Chagas disease (CD) worldwide. Caused by the parasite Trypanasoma cruzi , CD is generally a chronic condition. Diagnosis is logistically and financially challenging, requiring at least two different laboratory-based serological tests. Many CD cases are missed; in Bolivia it is estimated just 6% of individuals chronically infected with T . cruzi get diagnosed. Achieving control on the way to elimination of CD requires a radical simplification of the current CD testing pathways, to overcome the barriers to accessing CD treatment. We aimed to generate unbiased performance data of lateral flow assays (LFAs) for T . cruzi infection in Bolivia, to evaluate their usefulness for improving T . cruzi diagnosis rates in a precise and efficient manner. This retrospective, laboratory-based, diagnostic evaluation study sought to estimate the sensitivity/specificity of 10 commercially available LFAs for T . cruzi , using the current CD diagnostic algorithm employed in Bolivia as the reference test method. All tests were blinded at the study site and performed by three operators. In total, 470 serum samples were tested, including 221 and 249 characterized as CD-positive/-negative, respectively. The LFAs were scored according to their relative importance using a decision-tree-based algorithm, with the mean decrease in Gini index as the scoring metric. The estimates of sensitivities ranged from 62.2–97.7% (95% confidence interval (CI) lower bound 55.0–94.7%); for specificities the range was 78.6–100% (95% CI lower bound 72.0–97.5%); 5/10 and 6/10 tests had sensitivity >90% and specificity >95%, respectively. Four LFAs showed high values of both sensitivity (93–95%) and specificity (97–99%). The agreement between 6 LFAs and the reference tests was almost perfect (Kappa 0.83–0.94). Most LFAs evaluated thus showed performances comparable with current laboratory-based diagnostic methods. Chagas disease (CD) is caused by the parasite Trypanasoma cruzi . CD is generally a chronic condition. Individuals living in vulnerable situations and marginalized populations are often more susceptible to CD infection and morbidity, determined by, among other factors, a lack of access to timely diagnosis and care. However, diagnosing CD is difficult and expensive, requiring at least two different laboratory-based tests in highly specialized facilities, and many cases of CD go undiagnosed. In Bolivia, which has the highest incidence of CD worldwide, it is estimated that just 6% of chronically infected individuals get diagnosed. Lateral flow assays (LFAs) are tests that could be used to improve case management, especially in hard-to-reach populations, as they do not need specialized laboratories or highly trained people to use them. We carried out a study to evaluate LFAs that can be used for the rapid detection of CD infection, to evaluate their usefulness for diagnosis. Most of the tests we evaluated under controlled laboratory conditions were comparable to those of current laboratory-based diagnostic methods.

tropical medicine,parasitology
[Association between two different types of strangling and intraocular pressure variation in jiu-jitsu athletes].

M. J. Scarpi,M. Conte,Reginaldo Alexandre Rossin,Renato Skubs,Rudolf Eberhard Lenk,Rodrigo Brant

DOI: https://doi.org/10.1590/S0004-27492009000300011

2009-01-06

Arquivos Brasileiros de Oftalmologia

Abstract:PURPOSE To verify the association between two different types of strangling with intraocular pressure variation in jiu-jitsu athletes. METHODS An observational study was performed on 9 athletes of jiu-jitsu, with at least 6 month of training, male, aged 20 to 30 years, without any physical and eyeball lesions. Associations between intraocular pressure and Cross Choke from the guard strangling (E1), and E2 - Cross Choke from mount strangling were gotten. Intraocular pressure was determined by using Perkins tonometer, at first in the absence of physical exercise over the last 24 hours and after each strangling. Then it was carried out the intraocular pressure measure at each 3 minutes, during 12 minutes of exercise recovery (R1, R2, R3, and R4) keeping the athletes lied down. Statistical analysis was done using ANOVA test and Bonferroni post-test. RESULTS Meaningful reduction of both eyes intraocular pressure occurred at the E2 situation comparing to the E1 situation at all exercise recovery measures: R1 (OD: 8.22 +/- 1.39 vs.11.33 +/- 2.00 / OE: 8.55 +/- 1.23 vs. 11.88 +/- 1.90), R2 (OD: 8.44 +/- 1.87 vs.10.22 +/- 2.53 / OE: 9.00 +/- 1.80 vs. 10.44 +/- 2.35), R3 (OD: 8.44 +/- 1.74 vs.9.78 +/- 2.54 / OE: 8.55 +/- 1.42 vs. 10.33 +/- 1.93) all with p<0,01 e R4 (OD: 8.88 +/- 2.08 vs.9.55 +/- 2.87 / OE: 9.11 +/- 1.53 vs. 10.44 +/- 2.18) with p<0.05. Meaningful IOP reduction (p<0.05) was observed at the R1 moment of E2 strangling (OD: 10.77 +/- 1.92 vs.8.22 +/- 1.39 / OE: 11.44 +/- 1.94 vs. 8.55 +/- 1.23). CONCLUSION There is association between intraocular pressure and jiu-jitsu strangling exercises, with intraocular pressure reduction.
Human Trypanosoma cruzi infection in the Argentinean Chaco: risk factors and identification of households with infected children for treatment

Natalia P. Macchiaverna,Gustavo F. Enriquez,M Sol Gaspe,Lucía I. Rodríguez-Planes,Patricia R. Martinez,Ricardo E. Gürtler,M Victoria Cardinal

DOI: https://doi.org/10.1186/s13071-024-06125-8

2024-01-31

Parasites & Vectors

Abstract:Chagas disease is a neglected tropical disease (NTD). Cost-effective strategies for large-scale implementation of diagnosis and etiological treatment are urgently needed to comply with NTD control goals. We determined the seroprevalence of Trypanosoma cruzi infection and associated risk factors in a well-defined rural population of Pampa del Indio municipality including creole and indigenous (Qom) households and developed two indices to identify houses harboring infected children.

tropical medicine,parasitology
Community-based screening of Chagas disease among Latin American migrants in a non-endemic country: an observational study

Violeta Ramos-Sesma,Miriam Navarro,Jara Llenas-García,Concepción Gil-Anguita,Diego Torrus-Tendero,Philip Wikman-Jorgensen,María García-López,Concepción Amador-Prous,María-Paz Ventero-Martín,Pedro Guevara-Hernández,Ana Garijo-Saiz,Ares Sanchez-Sanchez,Cristina Bernal-Alcaraz,Ana-Isabel Pujades-Tarraga,Roser Muñoz-Perez,María Flores-Chávez,José-Manuel Ramos-Rincón,#CorazonesSinChagas Platform,Pedro B Guevara-Hernández,Joan Gregori-Colome,Ana Lucas-Dato,Esther Martínez-Birlanga,Estefanía García-Rodríguez,Diego Torrús-Tendero,M Paz Ventero-Martín,Adelin Gimeno-Gascón,Ares Sánchez-Sánchez,Roser Muñoz-Pérez,Carmen Almoedo-Albero,Concepción Amador Prous,Ana-Isabel Pujades-Tárraga,Antonio Santonja,María Sánchez-Valera,Rosa Sánchez-García,Miriam Navarro-Beltrá

DOI: https://doi.org/10.1186/s40249-021-00897-2

2021-09-15

Abstract:Background: Chagas disease is a parasitic disease endemic to Latin America, but it has become a disease of global concern due to migration flows. Asymptomatic carriers may host the parasite for years, without knowing they are infected. The aim of this study is to assess prevalence of Chagas disease and evaluate the participants' level of knowledge between Latin American migrants attending a community-based screening campaign. Methods: Three community-based campaigns were performed in Alicante (Spain) in 2016, 2017 and 2018, including educational chats and blood tests for Trypanosoma cruzi serology. Participants completed a questionnaire assessing knowledge about the mechanisms of transmission, disease presentation, diagnosis, and treatment. People seropositive for T. cruzi underwent diagnostic confirmation by two different tests. Results were analyzed by multivariable logistic regression and expressed as adjusted odds ratios (aORs), adjusting for age, sex, and time in Spain. Results: A total of 596 participants were included in the study; 17% were aged under 18 years. Prevalence in adults was 11% [54/496; 95% confidence interval (CI): 8.3-14.5%] versus 0% among children. All but one case were in Bolivians. Diagnosis was independently associated with having been born in Bolivia (aOR: 102, 95% CI: 13-781) and a primary school-level education (aOR: 2.40, 95% CI: 1.14-5.06). Of 54 people diagnosed with Chagas disease (most of whom were asymptomatic), 42 (77.7%) returned to the clinic at least once, and 24 (44.4%) received treatment. Multivariable analysis showed that coming from Argentina (aOR: 13, 95% CI: 1.61-1188) or Bolivia (aOR: 1.90, 95% CI: 1.19-3.39) and having received information about Chagas disease in Spain (aOR: 4.63, 95% CI: 2.54-8.97) were associated with a good level of knowledge on the disease. Having primary level studies (aOR: 0.59, 95% CI: 0.34-0.98) and coming from Ecuador (aOR: 4.63, 95% CI: 2.52-847) were independently associated with a lower level of knowledge. Conclusions: Community-based interventions are a good strategy for diagnosing neglected diseases such as Chagas disease in non-endemic countries and for identifying and treating infected, asymptomatic individuals.
In vitro diagnostic methods of Chagas disease in the clinical laboratory: a scoping review

Luis C. Ascanio,Savannah Carroll,Alberto Paniz-Mondolfi,Juan David Ramírez

DOI: https://doi.org/10.3389/fmicb.2024.1393992

IF: 5.2

2024-04-30

Frontiers in Microbiology

Abstract:Background: Chagas disease (CD), caused by Trypanosoma cruzi , is a global health concern with expanding geographical reach. Despite improved and accessible test methods, diagnosing CD in its various phases remains complex. The existence of clinical scenarios, including immunosuppressed patients, transplant-related CD reactivation, transfusion-associated cases, and orally transmitted acute infections, adds to the diagnostic challenge. No singular gold standard test exists for all phases, and recommendations from PAHO and the CDC advocate for the use of two serological methods for chronic CD diagnosis, while molecular methods or direct parasite detection are suggested for the acute phase. Given the complexity in the diagnostic landscape of CD, the goal of this scoping review is to characterize available diagnostic tests for CD in the clinical laboratory. Methods: A literature search in PubMed was conducted on studies related to In vitro diagnosis (IVD) in humans published in English, Spanish, or Portuguese language as of 28 August 2023, and extended backward with no predefined time frame. Studies underwent title and abstract screening, followed by full-text review. Studies included were classified based on the diagnostic method used. Test methods were grouped as serological, molecular, and other methods. Performance, availability, and regulatory status were also characterized. Results: Out of 85 studies included in the final review, 115 different tests were identified. These tests comprised 89 serological test types, 21 molecular test types, and 5 other test methods. Predominant serological tests included ELISA (38 studies, 44.70%), Rapid tests (19 studies, 22.35%), and chemiluminescence (10 studies, 11.76%). Among molecular tests, Polymerase Chain Reaction (PCR) assays were notable. Twenty-eight tests were approved globally for IVD or donor testing, all being serological methods. Molecular assays lacked approval for IVD in the United States, with only European and Colombian regulatory acceptance. Discussion and conclusion: Serological tests, specifically ELISAs, remain the most used and commercially available diagnostic methods. This makes sense considering that most Chagas disease diagnoses occur in the chronic phase and that the WHO gold standard relies on 2 serological tests to establish the diagnosis of chronic Chagas. ELISAs are feasible and relatively low-cost, with good performance with sensitivities ranging between 77.4% and 100%, and with specificities ranging between 84.2% and 100%. Molecular methods allow the detection of specific variants but rely on the parasite's presence, which limits their utility to parasitemia levels. Depending on the PCR method and the phase of the disease, the sensitivity ranged from 58.88 to 100% while the mean specificity ranged from 68.8% to 100%. Despite their performance, molecular testing remains mostly unavailable for IVD use. Only 3 molecular tests are approved for IVD, which are available only in Europe. Six commercial serological assays approved by the FDA are available for blood and organ donor screening. Currently, there are no guidelines for testing CD oral outbreaks. Although more evidence is needed on how testing methods should be used in special clinical scenarios, a comprehensive approach of clinical assessment and diagnostics tests, including not IVD methods, is required for an accurate CD diagnosis.

microbiology
The german Regiogeld system and its handling in everyday life

C. Thiel

DOI: https://doi.org/10.5282/UBM/EPUB.13773

Abstract:This paper introduces a special form of a community currency, the German Regiogeld System. Firstly it describes what it is, its origin and current status. Generally Regiogeld is a private monetary system with a regional validity and a non-profit-agenda. In detail the present 73 Regiogeld projects in Germany are quite different. This results from the fact that Regiogeld is originated in the fusing of different movements which affect its constructions and its objectives, its organizational, financial and personnel resources. Secondly, this paper focuses on the actual way of working in practice. It describes why consumers use this limited and costly form of money at all. In an interpretative process they earmark Regiogeld, by what qualitative different meanings and patterns of usages evolve. Thus Regiogeld can be used as affirmation of moral attitudes or as a sign for a symbolic community of ‘better’ people as well as an instrument of power that forces others into a local buying behaviour. Altogether, in the hands of the consumers Regiogeld multiplies to a bunch of different special monies. Understanding this process helps to understand how complementary currencies can be conceived, established and operated successfully.
Recombinant proteins as promising antigens applied to the immunodiagnosis of Chagas disease: a scoping review

Carlos Ananias Aparecido Resende,Anna Júlia Ribeiro,Isadora Braga Gandra,Kamila Alves Silva,Lucas da Silva Lopes,Isabelle Caroline Dos Santos Barcelos,Carolina Alves Petit Couto,Mariana Teixeira de Faria,Sabrina Paula Pereira,Sandra Rodrigues Xavier,Juliana Martins Machado,Mariana Campos da Paz,Ana Thereza Chaves,Eduardo Antônio Ferraz Coelho,Rodolfo Cordeiro Giunchetti,Miguel Angel Chávez-Fumagalli,Walderez Ornelas Dutra,Ana Alice Maia Gonçalves,Alexsandro Sobreira Galdino

DOI: https://doi.org/10.3389/fmicb.2024.1420226

2024-07-30

Abstract:Chagas disease (CD), caused by the protozoan Trypanosoma cruzi, is an important public health problem, occurring mainly in Latin America. The disease has a major social and economical effect, negatively impacting the life of the infected individuals, and bringing great costs to public health. An early and accurate diagnosis is essential for administration of early treatment. In addition, prognostic tests may aid disease management, decreasing hospitalization costs. However, the serological diagnostic scenario for CD still faces several challenges, making the development of new diagnostic kits a pressing matter. Facing this scenario, several researchers have expanded efforts in developing and testing new antigens, such as recombinant proteins and recombinant multiepitope proteins, with promising results. These recombinant antigens offer several advantages, such as improved sensitivity and specificity, in addition to facilitated scaling. Also, it has been possible to observe a rising number of studies using ELISA and point-of-care platforms, employing these antigens in the past few years. Among them, recombinant proteins were the most applied antigens, demonstrating great capacity to discriminate between positive and negative samples. Although fewer in number, recombinant multiepitope proteins also demonstrated an improved diagnostic performance. Indeed, a great number of studies employing these antigens showed sensitivity and specificity values above 90%, greatly impacting diagnostic accuracy. Nevertheless, despite the good results found, it is still possible to observe some bottlenecks in the development of new antigens, such as the scarcity of tests with sera from the acute phase and the variability of results in different geographic areas. In this sense, aiming to contribute to control and health programs, the continuous search for a more accurate serological diagnosis is essential, both for the acute and chronic phases of the disease.
Accuracy of chimeric proteins in the serological diagnosis of chronic chagas disease – a Phase II study

Fred Luciano Neves Santos,Paola Alejandra Fiorani Celedon,Nilson Ivo Tonin Zanchin,Wayner Vieira de Souza,Edimilson Domingos da Silva,Leonardo Foti,Marco Aurélio Krieger,Yara de Miranda Gomes

DOI: https://doi.org/10.1371/journal.pntd.0005433

2017-03-08

PLoS Neglected Tropical Diseases

Abstract:BACKGROUND: The performance of current serologic tests for diagnosing chronic Chagas disease (CD) is highly variable. The search for new diagnostic markers has been a constant challenge for improving accuracy and reducing the number of inconclusive results.METHODOLOGY/PRINCIPAL FINDINGS: Here, four chimeric proteins (IBMP-8.1 to -8.4) comprising immunodominant regions of different Trypanosoma cruzi antigens were tested by enzyme-linked immunosorbent assay. The proteins were used to detect specific anti-T. cruzi antibodies in the sera of 857 chagasic and 689 non-chagasic individuals to evaluate their accuracy for chronic CD diagnosis. The antigens were recombinantly expressed in Escherichia coli and purified by chromatographic methods. The sensitivity and specificity values ranged from 94.3% to 99.3% and 99.4% to 100%, respectively. The diagnostic odds ratio (DOR) values were 6,462 for IBMP-8.1, 3,807 for IBMP-8.2, 32,095 for IBMP-8.3, and 283,714 for IBMP-8.4. These chimeric antigens presented DORs that were higher than the commercial test Pathozyme Chagas. The antigens IBMP-8.3 and -8.4 also showed DORs higher than the Gold ELISA Chagas test. Mixtures with equimolar concentrations were tested in order to improve the diagnosis accuracy of negative samples with high signal and positive samples with low signal. However, no gain in accuracy was observed relative to the individual antigens. A total of 1,079 additional sera were used to test cross-reactivity to unrelated diseases. The cross-reactivity rates ranged from 0.37% to 0.74% even for Leishmania spp., a pathogen showing relatively high genome sequence identity to T. cruzi. Imprecision analyses showed that IBMP chimeras are very stable and the results are highly reproducible.CONCLUSIONS/SIGNIFICANCE: Our findings indicate that the IBMP-8.4 antigen can be safely used in serological tests for T. cruzi screening in blood banks and for chronic CD laboratory diagnosis.

tropical medicine,parasitology
How effective are rapid diagnostic tests for Chagas disease?

Maria-Jesus Pinazo,Joaquim Gascon,Julio Alonso-Padilla

DOI: https://doi.org/10.1080/14787210.2021.1873130

2021-01-11

Abstract:Introduction: Diagnosis of chronic Chagas disease relies on the agreement of two conventional serological tests based on distinct antigens. These require cold to preserve reagents and samples, and equipment and trained personnel to run them. Moreover, results turnaround may be delayed for several weeks risking a loss to follow-up of infected subjects, summoning major disadvantages to access diagnosis (and treatment) in many highly endemic areas. Areas covered: Recent studies have shown the versatility of rapid diagnostic tests for the detection of chronic Trypanosoma cruzi infections in referral centers and in field campaigns, with a performance equivalent to that of conventional tools. Remarkably, RDTs do not require cold storage and provide results within an hour. Additionally, they are easy-to-use and can work with a tiny volume of finger-pricked whole blood. Altogether, major advantages toward generalizing their use as an alternative to conventional tests. Expert opinion: Already in 2021, only a small percentage of T. cruzi-infected people are diagnosed and treated. The unsuitability of currently used diagnostics, and of the recommended algorithm, to the conditions found in many regions do not help to fill this gap. RDTs stand as a promising solution, even though geographical validation should precede their implementation.

pharmacology & pharmacy,infectious diseases,microbiology
The use of peptides for immunodiagnosis of human Chagas disease

Anna Julia Ribeiro,Kamila Alves Silva,Lucas da Silva Lopes,Carlos Ananias Aparecido Resende,Carolina Alves Petit Couto,Isadora Braga Gandra,Isabela Amorim Gonçalves Pereira,Isabelle Caroline Dos Santos Barcelos,Sabrina Paula Pereira,Sandra Rodrigues Xavier,Grasiele de Sousa Viera Tavares,Juliana Martins Machado,Mariana Campos Da Paz,Miguel Angel Chávez-Fumagalli,Eduardo Antonio Ferraz Coelho,Rodolfo Cordeiro Giunchetti,Ana Thereza Chaves,Walderez Ornelas Dutra,Ana Alice Maia Gonçalves,Alexsandro Sobreira Galdino

DOI: https://doi.org/10.1007/s00726-024-03394-6

IF: 3.7891

2024-05-08

Amino Acids

Abstract:Chagas disease, caused by the protozoa Trypanosoma cruzi , continues to be a serious public health problem in Latin America, worsened by the limitations in its detection. Given the importance of developing new diagnostic methods for this disease, the present review aimed to verify the number of publications dedicated to research on peptides that demonstrate their usefulness in serodiagnosis. To this end, a bibliographic survey was conducted on the PubMed platform using the keyword "peptide" or "epitope" combined with "Chagas disease" or " Trypanosoma cruzi "; "diagno*" or "serodiagnosis" or "immunodiagnosis", without period restriction. An increasing number of publications on studies employing peptides in ELISA and rapid tests assays was verified, which confirms the expansion of research in this field. It is possible to observe that many of the peptides tested so far originate from proteins widely used in the diagnosis of Chagas, and many of them are part of commercial tests developed. In this sense, as expected, promising results were obtained for several peptides when tested in ELISA, as many of them exhibited sensitivity and specificity values above 90%. Furthermore, some peptides have been tested in several studies, confirming their diagnostic potential. Despite the promising results observed, it is possible to emphasize the need for extensive testing of peptides, using different serological panels, in order to confirm their potential. The importance of producing an effective assay capable of detecting the clinical stages of the disease, as well as new immunogenic antigens that enable new serological diagnostic tools for Chagas disease, is evident.

biochemistry & molecular biology
Assessment of Alinity s Chagas® as a Primary Diagnostic Test for Chronic Chagas Disease in a Non-Endemic Area of Europe (Barcelona, Spain)

Alba Abras,Cristina Ballart,Anna Fernández-Arévalo,Teresa Llovet,Montserrat Gállego,Carmen Muñoz

DOI: https://doi.org/10.3390/life14101278

2024-10-10

Life

Abstract:Chagas disease (CD) has become a worldwide problem due to globalization. In Europe, most cases are imported and are diagnosed in the chronic phase by two serological tests, as recommended by the World Health Organization. Chemiluminescent microparticle immunoassays (CMIAs) are an emerging alternative to the diagnostic standard. We aimed to validate the CMIA Alinity s Chagas® as a primary diagnostic test for chronic CD following its replacement of Architect Chagas®, with an amended signal-to-cut-off (S/CO) ratio of ≥6. Laboratory results and clinical data were collected retrospectively from 774 sera from an at-risk population tested for CD in Barcelona during 2020–2022. Negative results required no further testing, and those with a S/CO ratio ≥ 0.8 were confirmed by a second serological assay, according to the common practice. Four per cent of the samples (31/774) were determined to be seropositive by Alinity s, 93.5% of which (29/31) had an S/CO ratio ≥ 6. Almost all the samples could be directly classified by the corrected S/CO. Alinity s Chagas® was validated as a single test for chronic CD diagnosis by raising the S/CO to ≥6. Its implementation could provide faster results and help reduce CD underdiagnosis in non-endemic countries.

biology
Effectiveness of once-weekly gym-based exercise programmes for older adults post discharge from day rehabilitation: a randomised controlled trial

A. Foley,Susan Hillier,R. Barnard

DOI: https://doi.org/10.1136/bjsm.2009.063966

IF: 18.4793

2010-03-09

British Journal of Sports Medicine

Abstract:Objective To determine whether high-intensity, progressive gym-based exercise performed once a week is as effective as twice weekly for maintaining both subjective and objective outcomes in older adults post discharge from a metropolitan day rehabilitation centre (DRC). Design Randomised controlled trial. Setting Community-based exercise centre for older adults, located in Metropolitan Adelaide, South Australia. Participants 21 men and 85 women who completed the DRC programme were assessed and randomly allocated to a study group. Intervention The two experimental interventions were gym-based exercise programmes (including resistance, aerobic, flexibility and balance training) varying only in frequency of delivery: either once or twice a week, directly compared with usual care (control). Main outcome measures Lower limb strength (one-repetition maximum), balance (Berg Balance Scale), physical function (gait speed, 30-s chair stand test, timed up and go test (primary outcome) and 6-min walk test), self-reported pain (Glasgow Pain Questionnaire), activities of daily living (Barthel Index and Older Americans Resources and Services Multidimensional Functional Assessment Questionnaire), perceived benefits of and barriers to exercise (Exercise Benefits Barriers Scale), quality of life (Assessment of Quality of Life Questionnaire) and exercise frequency preference. Results Most of the outcomes (69%, 11/16) were maintained over the intervention period with no significant group effects detected between the two intervention groups or compared to the control group. Physical activity levels recorded in the control group showed a significant proportion of participants were actively exercising once weekly. A per-protocol analysis was undertaken to take this potential contamination effect into account. This showed that the control group participants, who did not exercise, did not maintain outcomes to the extent of the intervention groups, with significant group-by-time effects detected between the two intervention groups and the control group. Most of all participants (66%, 62/94) nominated once a week as their preferred exercise frequency. Conclusions The overall finding of no significant differences between the two intervention groups for all outcomes measured gives support to the effectiveness of once-a-week exercise in maintaining outcomes at 3 months post rehabilitation. Further research is warranted given the once-a-week exercise intervention should cost less, had higher compliance and was nominated as the preferred exercise frequency by most of the participants.
Detecting Areas of Potential High Prevalence of Chagas in Argentina

Antonio Vazquez Brust,Tomas Olego,German Rosati,Carolina Lang,Guillermo Bozzoli,Diego Weinberg,Roberto Chuit,Martin A. Minnoni,Carlos Sarraute

DOI: https://doi.org/10.48550/arXiv.2001.00604

2020-01-02

Social and Information Networks

Abstract:A map of potential prevalence of Chagas disease (ChD) with high spatial disaggregation is presented. It aims to detect areas outside the Gran Chaco ecoregion (hyperendemic for the ChD), characterized by high affinity with ChD and high health vulnerability. To quantify potential prevalence, we developed several indicators: an Affinity Index which quantifies the degree of linkage between endemic areas of ChD and the rest of the country. We also studied favorable habitability conditions for Triatoma infestans, looking for areas where the predominant materials of floors, roofs and internal ceilings favor the presence of the disease vector. We studied determinants of a more general nature that can be encompassed under the concept of Health Vulnerability Index. These determinants are associated with access to health providers and the socio-economic level of different segments of the population. Finally we constructed a Chagas Potential Prevalence Index (ChPPI) which combines the affinity index, the health vulnerability index, and the population density. We show and discuss the maps obtained. These maps are intended to assist public health specialists, decision makers of public health policies and public officials in the development of cost-effective strategies to improve access to diagnosis and treatment of ChD.
Chagas Disease Serological Test Performance in U.S. Blood Donor Specimens

Jeffrey D Whitman,Christina A Bulman,Emma L Gunderson,Amanda M Irish,Rebecca L Townsend,Susan L Stramer,Judy A Sakanari,Caryn Bern

DOI: https://doi.org/10.1128/JCM.01217-19

2019-11-22

Abstract:Chagas disease affects an estimated 300,000 individuals in the United States. Diagnosis in the chronic phase requires positive results from two different IgG serological tests. Three enzyme-linked immunosorbent assays (ELISAs) (Hemagen, Ortho, and Wiener) and one rapid test (InBios) are FDA cleared, but comparative data in U.S. populations are sparse. We evaluated 500 seropositive and 300 seronegative blood donor plasma samples. Country of birth was known for 255 seropositive specimens, which were grouped into regions as follows: Mexico (n = 94), Central America (n = 88), and South America (n = 73). Specimens were tested by the four FDA-cleared IgG serological assays. Test performance was evaluated by two comparators and latent class analysis. InBios had the highest sensitivity (97.4% to 99.3%) but the lowest specificity (87.5% to 92.3%). Hemagen had the lowest sensitivity (88.0% to 92.0%) but high specificity (99.0% to 100.0%). The level of sensitivity was intermediate for Ortho (92.4% to 96.5%) and Wiener (94.0% to 97.1%); both had high specificity (98.8% to 100.0% and 96.7% to 99.3%, respectively). The levels of antibody reactivity and clinical sensitivity were lowest in donors from Mexico, intermediate in those from Central America, and highest in those from South America. Our findings provide an initial evidence base to improve laboratory diagnosis of Chagas disease in the United States. The best current testing algorithm would employ a high-sensitivity screening test followed by a high-specificity confirmatory test.
Dissimilar Trypanosoma cruzi genotype-specific serological profile assessed by Chagas-Flow ATE IgG1 upon benznidazole etiological treatment of chronic Chagas disease

Glaucia Diniz Alessio,Carolina Malheiros Araújo Silvestrini,Silvana Maria Elói-Santos,Eliane Dias Gontijo,Policarpo Ademar Sales Júnior,Danielle Marchetti Vitelli-Avelar,Renato Sathler-Avelar,Ana Paula Barbosa Wendling,Andréa Teixeira-Carvalho,Marta de Lana,Olindo Assis Martins-Filho

DOI: https://doi.org/10.1371/journal.pntd.0012487

2024-09-14

PLoS Neglected Tropical Diseases

Abstract:The present study aimed to verify the impact of etiological treatment on the genotype-specific serological diagnosis of chronic Chagas disease patients (CH), using the Chagas-Flow ATE IgG1 methodology. For this purpose, a total of 92 serum samples from CH, categorized as Not Treated (NT, n = 32) and Benznidazole-Treated (Bz-T, n = 60), were tested at Study Baseline and 5 Years Follow-up. At Study Baseline, all patients have the diagnosis of Chagas disease confirmed by Chagas-Flow ATE IgG1, using the set of attributes ("antigen/serum dilution/cut-off"; "EVI/250/30%"). The genotype-specific serodiagnosis at Study Baseline demonstrated that 96% of patients (44/46) presented a serological profile compatible with TcII genotype infection. At 5 Years Follow-up monitoring, NT and Bz-T presented no changes in anti-EVI IgG1 reactivity. However, significant differences were detected in the genotype-specific IgG1 reactivity for Bz-T. The most outstanding shift comprised the anti-amastigote TcVI/(AVI), anti-amastigote TcII/(AII) and anti-epimastigote TcVI/(EVI) reactivities. Regardless no changes in the genotype-specific serology of NT (TcI = 6%; TcII = 94%), distinct T . cruzi genotype-specific sero-classification was detected for Bz-T samples at 5 Years Follow-up (TcII = 100%) as compared to Baseline (TcII = 97%; TcVI = 3%). The anti-trypomastigote TcI/(TI) was the attribute accountable for the change in genotype-specific sero-classification. In conclusion, our findings of dissimilar T . cruzi genotype-specific serology upon Bz-treatment re-emphasize the relevance of accomplishing the genotype-specific serodiagnosis during clinical pos-therapeutic management of chronic Chagas disease patients. Chagas disease is still a serious public health problem worldwide. Currently, only two drugs are available for the treatment of patients infected by T . cruzi : Benzonidazole and Nifurtimox. The efficacy of these compounds may differ depending on the phase of the disease when the treatment is established and also impacted by the T . cruzi genotypes that cause the infection. Thus, differences in therapeutic efficacy can be observed between geographic areas due to the distinct distribution of " Discrete Typing Unitys " (DTUs) of T . cruzi . Besides all these matters related to the etiological treatment, additional concerns regarding the laboratorial methods available for post-therapeutic monitoring of Chagas disease represent a challenge during clinical management. Amongst the innovative serological approaches, proposed for diagnosis and post-therapeutic monitoring of Chagas disease, the Chagas-Flow ATE IgG1 has been presented as an outstanding methodology, applicable for universal and genotype-specific serology. In the present study, the Chagas-Flow ATE IgG1 methodology was used for post-therapeutic monitoring of chronic Chagas disease patients, aiming at identifying changes in T . cruzi genotype-specific serological profile upon Benznidazole etiological treatment. This approach is relevant to provide novel insights to support the relevance of accomplishing the genotype-specific serodiagnosis during clinical pos-therapeutic management of chronic Chagas disease patients.

tropical medicine,parasitology
Improving Clinician Awareness of and Screening for Chagas Disease with an Educational Intervention

Alyse Wheelock,Sukhmeet Sandhu,Katherine Reifler,Malwina Carrion,Daniel L Bourque,Davidson H Hamer,Natasha S Hochberg

DOI: https://doi.org/10.4269/ajtmh.23-0483

2024-06-18

Abstract:Chagas disease is an underrecognized, chronic, and potentially life-threatening disease caused by the parasite Trypanosoma cruzi. We aimed to improve awareness and screening for Chagas disease among patients from endemic areas using a large safety-net academic hospital system in the United States. We developed an educational intervention consisting of a case-based didactic session presented to physicians, trainees, and other healthcare providers at conferences across different departments. Performance on a knowledge assessment administered before and after the presentation was analyzed with paired Student's t-test for within-subject difference testing. Institutional testing rates for T. cruzi were evaluated for an equal time period (29 months) before and after the start of the intervention. Testing rates were compared by a Welch's unequal variances t-test and by interrupted time series based on multivariate linear regression. Eleven educational sessions were held over the intervention period, and 103 participants completed the pre- and post-presentation surveys. The mean survey scores were 59.2% before the presentation and 96.6% after presentation (P <0.001). Trypanosoma cruzi testing during the postintervention period was significantly higher than testing during the pre-intervention period (171 patients pre-intervention versus 378 patients postintervention [P = 0.015]). Notable increases in testing from the pre-intervention to postintervention periods occurred among midwives (1-68 patients tested) and trainees (57-133 patients tested). Overall, 56/537 (10.4%) nonduplicate T. cruzi commercial screening tests were positive. Testing increased over time, both at an institutional level and within targeted departments. In addition to the educational program, other factors likely influenced expanded testing.
Electrochemical Impedance Biosensor for Chagas Disease Diagnosis in Clinical Samples

J. S. Cisneros,Cecilia Yamil Chain,M. A. Daza Millone,C. A. Labriola,K. Scollo,A. M. Ruiz,P. Estrela,M. E. Vela

DOI: https://doi.org/10.2139/ssrn.4132275

2022-01-01

SSRN Electronic Journal

Abstract:In this study, we describe a novel biosensor platform for the rapid detection of Chagas Disease (CD), from serum samples. The most widely used detection methods for CD are serological tests. However, they require centralized testing, which severely limits the ability of the disease to be diagnosed in communities with scarce resources. Unlike most serological methods for diagnosing CD, which rely on either semi-purified antigenic fractions from Trypanosoma cruzi or recombinant proteins, this immunoassay is based on a highly antigenic and parasite-isolated protein (cruzipain). Cruzipain (CrP) from T. cruzi was covalently immobilized onto gold electrodes via a mixed 11-mercaptoundecanoic and 6-mercapto-1-hexanol self-assembled monolayer. Different sensor surfaces based in CrP were obtained and qualitatively and quantitatively characterized by cyclic voltammetry (CV) and Surface Plasmon Resonance (SPR) as complementary surface analytical techniques at the successive functionalization steps. Electrochemical impedance spectroscopy (EIS) was used for detecting the presence of anti- T. cruzi antibodies in archived serum samples from patients both positive and negative for CD. The charge transfer resistance of the biosensors increases by ~20% in the presence of the positive samples, whereas the negative samples give rise to a small increase of around 6%. An excellent selectivity to clinical samples from patients infected with T. cruzi was obtained. The clear signal difference obtained for positive and negative clinical samples highlights the applicability of the sensors for the point-of-care diagnosis of CD.
Diversity of Chagas disease diagnostic antigens: Successes and limitations

Tapan Bhattacharyya,Niamh Murphy,Michael A. Miles

DOI: https://doi.org/10.1371/journal.pntd.0012512

2024-10-02

PLoS Neglected Tropical Diseases

Abstract:Chagas disease, caused by the protozoan parasite Trypanosoma cruzi , remains a public health issue in endemic regions of the Americas, and is becoming globalised due to migration. In the chronic phase, 2 accordant serological tests are required for diagnosis. In addition to "in-house" assays, commercial tests are available (principally ELISA and rapid diagnostic tests). Herein, we discuss the discovery era of defined T . cruzi serological antigens and their utilisation in commercialised tests. A striking feature is the re-discovery of the same antigens from independent studies, and their overlapping use among commonly reported commercial serological tests. We also consider reports of geographical variation in assay sensitivity and areas for refinement including applications to congenital diagnosis, treatment monitoring, and lineage-specific antigens.

tropical medicine,parasitology

Virtual Reality Visualization for Photogrammetric 3D Reconstructions of Cultural Heritage

Comparative evaluation of four rapid diagnostic tests that detect human Trypanosoma cruzi- specific antibodies to support diagnosis of Chagas Disease in urban population of Argentina

Comparative evaluation of lateral flow assays to diagnose chronic Trypanosoma cruzi infection in Bolivia

[Association between two different types of strangling and intraocular pressure variation in jiu-jitsu athletes].

Human Trypanosoma cruzi infection in the Argentinean Chaco: risk factors and identification of households with infected children for treatment

Community-based screening of Chagas disease among Latin American migrants in a non-endemic country: an observational study

In vitro diagnostic methods of Chagas disease in the clinical laboratory: a scoping review

The german Regiogeld system and its handling in everyday life

Recombinant proteins as promising antigens applied to the immunodiagnosis of Chagas disease: a scoping review

Accuracy of chimeric proteins in the serological diagnosis of chronic chagas disease – a Phase II study

How effective are rapid diagnostic tests for Chagas disease?

The use of peptides for immunodiagnosis of human Chagas disease

Assessment of Alinity s Chagas® as a Primary Diagnostic Test for Chronic Chagas Disease in a Non-Endemic Area of Europe (Barcelona, Spain)

Effectiveness of once-weekly gym-based exercise programmes for older adults post discharge from day rehabilitation: a randomised controlled trial

Detecting Areas of Potential High Prevalence of Chagas in Argentina

Chagas Disease Serological Test Performance in U.S. Blood Donor Specimens

Dissimilar Trypanosoma cruzi genotype-specific serological profile assessed by Chagas-Flow ATE IgG1 upon benznidazole etiological treatment of chronic Chagas disease

Improving Clinician Awareness of and Screening for Chagas Disease with an Educational Intervention

Electrochemical Impedance Biosensor for Chagas Disease Diagnosis in Clinical Samples

Diversity of Chagas disease diagnostic antigens: Successes and limitations